A tumor vaccine CRS-207 utilizing a live attenuated strain of bacterium Listeria monocytogenes (Lm) expressing human MSLN has shown good tolerance and MSLN-specific T-cell response in a phase I study of safety clinical trial. Here, MSLN is linked to neoplasm.